Figure 2: ATM expression and activity promotes HER2 tumorigenicity in vivo.
From: ATM kinase sustains HER2 tumorigenicity in breast cancer
(a–c) MCF7-HER2shR5 and MCF7-HER2shATM cells were subcutaneously injected into nude mice and tumour growth was monitored. (a) Quantification of tumour size during 5 weeks of xenograft growth. (b) Pictures representative of tumours after dissection. (c) Comparison of tumour size between MCF7-HER2shR5 and MCF7-HER2shATM xenografts. Each plot graphically shows the central location and scatter/dispersion of the values of each group: the line series in the rectangular shaped box indicate the median value of the data and the end of vertical lines indicates the minimum and the maximum data value. The mean and its confidence interval are shown in the diamond shape box. P value was calculated according to independent samples t-test (n=22). (d–f) FBV-NeuT mice were intraperitoneally injected with 10 mg kg−1 KU-55933 in DMSO or with DMSO as control, every 2 days for 2 weeks starting from the appearance of the first mammary tumour, and sacrificed 3 days after the last injection. ATM-p was revealed by immunohistochemistry on tumours, scale bars, 30 μm (d). Tumour growth curves showing delayed tumour onset and reduced tumour incidence (e) and reduced relative tumour volume growth (f) of KU-55933-injected mice versus DMSO control mice. Data are shown as mean+s.d. (* indicates the P value for KU-55933 versus DMSO; P values were calculated using two-sided Student’s t-tests).
